Enterprise Value
-12.72M
Cash
25.19M
Avg Qtr Burn
-5.741M
Short % of Float
0.90%
Insider Ownership
0.00%
Institutional Own.
6.46%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PHAXIAM phages Details Endocarditis infections, Staph aureus | Phase 1 Data readout | |
Eryaspase (GRASPA) (asparaginase) Details Pancreatic cancer, Solid tumor/s, Cancer | Failed Discontinued | |
Eryaspase (GRASPA) (asparaginase) Details Leukemia, Acute lymphoblastic leukemia, Cancer | Failed Discontinued | |
Eryaspase (GRASPA) (asparaginase) Details Pancreatic cancer, Cancer | Failed Discontinued | |
Eryaspase (GRASPA) (asparaginase) Details Breast cancer, Triple-negative breast cancer , Cancer | Failed Discontinued |